Events News Research CBS CBS Publications Bioinformatics
Staff Contact About Internal CBS CBS Other

Abstract


Reference

The role of the proteasome in generating cytotoxic T cell epitopes: Insights obtained from improved predictions of proteasomal cleavage M. Nielsen, C. Lundegaard, S. Brunak, O. Lund, and C. Kesmir. Manuscript accepted for publication in European Journal of Immunology May 2005.

Abstract

Reverse immunogenetic approaches attempt to optimize the selection of candidate epitopes and thus minimize the experimental effort needed to identify new epitopes. When predicting CTL epitopes, the main focus has been on the highly specific MHC class I binding event. Methods have also been developed for predicting the antigen processing steps preceding MHC class I binding including proteasomal cleavage and transporter associated with antigen processing (TAP) transport efficiency. Here, we use a dataset obtained from the SYFPEITHI database to show that a method integrating predictions of MHC class I binding affinity, TAP transport efficiency, and C-terminal proteasomal cleavage outperforms any of the individual methods. Using an independent evaluation dataset of HIV epitopes from the Los Alamos database, the validity of the integrated method is confirmed. The performance of the integrated method is found to be significantly higher than that of the two publicly available prediction methods BIMAS and SYFPEITHI. In order to identify 85% of the epitopes in the HIV dataset, 9% and 10% of all possible 9mers in the HIV proteins must be tested if using the BIMAS and SYFPEITHI methods, respectively, for the selection of candidate epitopes. This number is reduced to 7% when using the integrated method. In practical terms, this means that the experimental effort needed in order to identify an epitope in a hypothetical protein with 85% probability is reduced by 20-30% when using the integrated method. The method is available at http://www.cbs.dtu.dk/services/NetCTL. Supplementary material is available at http://www.cbs.dtu.dk/suppl/immunology/CTL.php.




CORRESPONDENCE

Morten Nielsen,